Claritin Generic Competition Grows As Impax Version Granted FDA Approval
This article was originally published in The Tan Sheet
Executive Summary
FDA approval of a generic version of Schering-Plough's OTC Claritin Reditabs (loratadine 10 mg) is expected to make further inroads into the $175 mil. product
You may also be interested in...
Schering Compliance Appointment Reflects Hassan’s Pursuit Of GMP Closure
Schering-Plough's appointment of Brent Saunders as senior VP-global compliance & business practices is indicative of CEO Fred Hassan's aggressive strategy of addressing the firm's compliance issues
Schering CEO Hassan Will Add Personal Touch To Allergy Business Turnaround
Schering-Plough CEO Fred Hassan will be directly involved in reviving the firm's declining allergy business following the Rx-to-OTC switch of Claritin in December 2002
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC